Diversified science and technology company Danaher (NYSE: DHR) beat Wall Street’s revenue expectations in Q3 CY2025, with sales up 4.4% year on year to $6.05 billion. On the other hand, next quarter’s revenue guidance of $6.70 billion was less impressive, coming in 4.7% below analysts’ estimates. Its non-GAAP profit of $1.89 per share was 9.8% above analysts’ consensus estimates.

Is now the time to buy DHR? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Danaher’s third quarter was marked by solid execution across its core businesses, with management citing bioprocessing momentum and a stronger-than-anticipated performance in respiratory diagnostics as key drivers. CEO Rainer Blair highlighted that demand for monoclonal antibody production remained robust, propelling bioprocessing growth, while Cepheid’s respiratory testing revenues benefited from customers ordering earlier than usual. Management also pointed to disciplined cost management and ongoing productivity initiatives as contributing to improved margins, despite continued softness in academic and government funding.

Looking forward, Danaher’s outlook reflects both cautious optimism and ongoing external uncertainties. Management is planning for modest recovery across end markets, particularly in bioprocessing and diagnostics, while also factoring in persistent policy headwinds in China and restrained life sciences research spending. CFO Matt McGrew noted the company is anchoring growth expectations at the lower end of its guidance range, emphasizing, “We’re going to be in a really good position to deliver high single-digit EPS growth even if we end up at the low end of that range.”

Key Insights from Management’s Remarks

Management attributed the quarter’s growth to continued strength in bioprocessing consumables, robust recurring revenues, and operational discipline despite geopolitical and policy challenges.

• Bioprocessing consumables drive growth: Demand for monoclonal antibody production underpinned high single-digit growth in bioprocessing consumables, offsetting slower equipment orders as customers awaited more policy clarity.
• Diagnostics segment resilience: Beckman Coulter and Leica Biosystems achieved mid-single-digit or higher growth outside China, supported by new product launches like the DxI 9000 analyzer and adoption of digital pathology tools.
• Early respiratory season lifts Cepheid: Respiratory diagnostic revenues at Cepheid exceeded expectations as health systems purchased tests earlier than usual, contributing to overall diagnostics outperformance.
• Cost management and productivity initiatives: The company’s focus on structural cost reduction and productivity investments led to improved operating margins, with $175 million in cost actions set to yield $250 million in savings next year.
• Geopolitical and policy adaptation: Management highlighted ongoing mitigation of headwinds from China’s volume-based procurement and reimbursement policy changes, as well as efforts to localize manufacturing to navigate emerging regulatory requirements.

Drivers of Future Performance

Danaher’s guidance is shaped by expectations for steady bioprocessing demand, productivity-driven margin improvement, and cautious assumptions around life sciences and China.

• Continued bioprocessing strength: Management expects demand for biologics, especially monoclonal antibodies, to drive high single-digit growth in bioprocessing consumables, while equipment sales are projected to remain flat until policy clarity improves.
• Diagnostics momentum and China headwinds: Diagnostic growth is anticipated to accelerate as the company laps policy-related disruptions in China, but management remains conservative, assuming only moderate improvement in the region due to ongoing regulatory uncertainty.
• Productivity and margin expansion: A planned $175 million in cost reductions and operational efficiencies are expected to deliver over 100 basis points of adjusted operating margin expansion, supporting high single-digit non-GAAP EPS growth even if top-line growth is at the low end of the range.

Catalysts in Upcoming Quarters

In the quarters ahead, the StockStory team will monitor (1) whether bioprocessing equipment demand rebounds as policy clarity emerges and capital projects move forward, (2) the pace of diagnostics growth as China policy headwinds subside and new product adoption accelerates, and (3) realization of margin improvements from announced cost actions. The evolution of regulatory environments and the impact of regional manufacturing strategies will also be important to watch.

Danaher currently trades at $223.99, up from $208.28 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free for active Edge members).

Stocks That Trumped Tariffs

When Trump unveiled his aggressive tariff plan in April 2025, markets tanked as investors feared a full-blown trade war. But those who panicked and sold missed the subsequent rebound that’s already erased most losses.

Don’t let fear keep you from great opportunities and take a look at Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.